Asian Tech Press (Nov 7) -- Chinese drugmaker Walvax (300142.SZ) said Monday it is now focusing on developing markets in Southeast Asia, the Middle East and North Africa, and South America.

Walvax Biotechnology Co Ltd said on the Shenzhen Stock Exchange's investor interactive platform that the company's international market is now focusing on exploring Southeast Asia, the Middle East and North Africa, South America and other countries and regions with fast-growing populations and large volumes.

The company said it has been the sole global supplier of A/C polysaccharide vaccine for the Egyptian government's national immunization program for five consecutive years since 2018.

In August this year, Walvax signed an agreement with its Egyptian partner for distribution and localized production cooperation of 13-valent pneumococcal polysaccharide conjugate vaccine (PCV-13) in Egypt and its neighboring countries.